ASH 2025: THE 67TH ANNUAL MEETING & EXPOSITION

ASH 2025: 67th Annual Meeting & Exposition

+ Target Audience: hematologist-oncologists, pathologists

+ Information:

ASH 2025: THE 67TH ANNUAL MEETING & EXPOSITION

“Defining the Future of Blood: Gene Therapy, Immunotherapy & Beyond”

Conference Dates: December 6 – 9, 2025  Location: Orlando, Florida Academic Host: American Society of Hematology (ASH)

 General Information

Welcome to the “Super Bowl” of Hematology. The ASH Annual Meeting is the global benchmark where practice-changing data is released. If it happens in blood, it happens here.

The 2025 meeting in Orlando presented hematology research and educational sessions. Conference findings require critical appraisal and do not, by themselves, establish treatment standards or guarantee clinical outcomes.

• Format: Scientific Plenary Sessions + Education Programs + Satellite Symposia.

• Scope: Malignant and non-malignant hematology, including coagulation.

 Target Audience

These educational materials are intended for:

1. Hematologist-Oncologists: Who need to decide between Bispecific Antibodies and CAR-T therapy for their relapsed Myeloma and Lymphoma patients.

2. Pathologists: Integrating AI-driven diagnostics and next-gen sequencing (NGS) into daily reporting.

3. Transplant Physicians: Managing the toxicities of cellular therapies (CRS/ICANS) in an outpatient setting.

4. General Practitioners/Hospitalists: Who need to recognize the “red flags” of hematologic emergencies and manage the long-term survivors of gene therapy.

 Learning Objectives

The following are proposed study areas, not a verified list of included sessions or a guarantee of clinical competence:

1. Revolutionize Myeloma Care: Apply the 2025 algorithms for Quadruplet Therapy in newly diagnosed Multiple Myeloma and sequence BCMA-targeted agents in relapse.

2. Review Gene Therapies: Distinguish Casgevy, a genome-editing therapy, from Lyfgenia, a lentiviral-vector gene therapy. Lyfgenia is indicated for sickle cell disease, not beta-thalassemia; eligibility and safety requirements must be checked against the relevant product labeling.

3. Target AML Precision: Utilize Menin Inhibitors for KMT2A-rearranged and NPM1-mutated acute myeloid leukemia.

4. Manage Hemophilia: Transition patients from factor replacement to Gene Therapy (Hemgenix/Roctavian) and non-factor replacement therapies.

 Course Topics & Tracks (2025 Predictions)

The curriculum focuses on the highest-yield clinical areas.

TOPIC 1: The Myeloma & Lymphoma Revolution

• Bispecifics vs. CAR-T: The “Great Debate.” When to use “off-the-shelf” antibodies (Teclistamab, Talquetamab) versus autologous cell therapy.

• MCL & CLL: Moving towards “Chemo-Free” combinations (BTK inhibitors + BCL2 inhibitors) as first-line standards.

TOPIC 2: Leukemia & Myeloid Malignancies

• AML Updates: The rise of “Triplet” therapies (HMA + Venetoclax + Novel Agent) for the unfit patient.

• MDS Classification: Mastering the new WHO vs. ICC classifications—it’s not just “MDS” anymore; it’s molecularly defined.

TOPIC 3: Non-Malignant Hematology (Red Cell & Coag)

• Sickle Cell Cure: Real-world data on the first cohort of patients treated with CRISPR gene editing—safety, off-target effects, and fertility preservation.

• ITP & TTP: New agents targeting the complement system and FcRn inhibitors.

TOPIC 4: Immuno-Oncology & Toxicity Management

• CRS & ICANS: Review of cytokine release syndrome and neurotoxicity; escalation and intensive-care needs depend on severity, specialist assessment, and current protocols.

• Infection Prevention: Prophylaxis strategies for the profoundly immunosuppressed patient on B-cell maturation antigen (BCMA) therapy.